- Home
- PSNY vs VRDN Comparison
PSNY vs VRDN Comparison
Compare PSNY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNY
- VRDN
- Stock Information
- Founded
- PSNY 2017
- VRDN 2006
- Country
- PSNY Sweden
- VRDN United States
- Employees
- PSNY N/A
- VRDN N/A
- Industry
- PSNY Auto Manufacturing
- VRDN Medical Specialities
- Sector
- PSNY Consumer Discretionary
- VRDN Health Care
- Exchange
- PSNY Nasdaq
- VRDN Nasdaq
- Market Cap
- PSNY 1.8B
- VRDN 1.6B
- IPO Year
- PSNY N/A
- VRDN N/A
- Fundamental
- Price
- PSNY $0.71
- VRDN $22.61
- Analyst Decision
- PSNY Hold
- VRDN Strong Buy
- Analyst Count
- PSNY 2
- VRDN 11
- Target Price
- PSNY $1.25
- VRDN $39.20
- AVG Volume (30 Days)
- PSNY 3.9M
- VRDN 1.5M
- Earning Date
- PSNY 09-03-2025
- VRDN 11-13-2025
- Dividend Yield
- PSNY N/A
- VRDN N/A
- EPS Growth
- PSNY N/A
- VRDN N/A
- EPS
- PSNY N/A
- VRDN N/A
- Revenue
- PSNY $2,547,619,000.00
- VRDN $305,000.00
- Revenue This Year
- PSNY $82.42
- VRDN N/A
- Revenue Next Year
- PSNY $47.97
- VRDN $37,670.06
- P/E Ratio
- PSNY N/A
- VRDN N/A
- Revenue Growth
- PSNY 24.82
- VRDN 5.90
- 52 Week Low
- PSNY $0.70
- VRDN $9.90
- 52 Week High
- PSNY $1.42
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PSNY 21.87
- VRDN 53.59
- Support Level
- PSNY $0.83
- VRDN $21.65
- Resistance Level
- PSNY $0.90
- VRDN $24.23
- Average True Range (ATR)
- PSNY 0.04
- VRDN 1.11
- MACD
- PSNY -0.01
- VRDN -0.11
- Stochastic Oscillator
- PSNY 6.13
- VRDN 28.51
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).